+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Biomarkers Market by Type, Disease Indication, Technology, Application, End-User - Global Forecast to 2030- Product Image
Central Nervous System Biomarkers Market by Type, Disease Indication, Technology, Application, End-User - Global Forecast to 2030- Product Image
Sale

Central Nervous System Biomarkers Market by Type, Disease Indication, Technology, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010785
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The central nervous system biomarkers market is rapidly evolving as research converges with technological innovation to enhance diagnostics, precision medicine, and therapeutic strategies. Senior decision-makers face heightened demand for actionable intelligence to navigate shifts in clinical applications, regulatory policies, and global supply chains.

Market Snapshot: Central Nervous System Biomarkers

The Central Nervous System Biomarkers Market grew from USD 4.80 billion in 2024 to USD 5.19 billion in 2025. It is projected to continue its upward trajectory at a CAGR of 7.72%, reaching USD 7.50 billion by 2030. This growth reflects intensifying needs for early and accurate detection of neurological and psychiatric conditions, supported by advancements in multi-omics technologies, data analytics, and collaborative industry efforts.

Scope & Segmentation

  • Type: Genomic biomarkers, metabolomic biomarkers, proteomic biomarkers
  • Disease Indications: Neurodegenerative diseases, neurodevelopmental disorders, psychotic disorders
  • Technology: Immunoassay (ELISA, Western blot), mass spectrometry (gas chromatography coupled, liquid chromatography coupled), next-generation sequencing (targeted sequencing, whole genome sequencing)
  • Application: Diagnosis and therapeutics, drug discovery and development, personalized medicine, prognosis, research and development
  • End-User: Academic research institutes, healthcare providers, pharmaceutical companies
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and more), Asia-Pacific (including China, India, Japan, Australia, and others)
  • Leading Companies: Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, Charles River Laboratories, F. Hoffmann-La Roche, Johnson & Johnson Services, Merck & Co., Novartis, Qiagen, Siemens Healthineers, Thermo Fisher Scientific Inc., and others

Key Takeaways for Senior Decision-Makers

  • Multi-omics integration is expanding the toolkit for identifying sensitive and specific biomarkers supporting early disease intervention and personalized therapy selection.
  • Collaborative efforts among academic centers, biotech start-ups, and pharmaceutical companies are advancing both assay development and regulatory acceptance.
  • Incorporating artificial intelligence and machine learning is streamlining discovery, enabling cross-platform analysis of complex datasets, and improving clinical trial efficiency.
  • Regional strategies are increasingly important, as local regulatory pathways, reimbursement structures, and infrastructural maturity influence market penetration and competitive positioning.
  • Service diversification is intensifying, with key players broadening offerings to include digital analytics, regulatory consulting, and end-to-end biomarker solutions aligned with evolving healthcare needs.
  • Market participants are leveraging co-development partnerships, mergers, and geographic expansion to optimize resource allocation and mitigate regulatory and operational risks.

Tariff Impact on CNS Biomarker Supply Chains

Beginning January 2025, revised US tariffs affecting diagnostic reagents and advanced laboratory instrumentation are expected to increase cost pressures across the supply chain. Higher import duties on key consumables and instruments are likely to translate into elevated costs for research, diagnostics, and manufacturing operations. Companies are responding with supplier diversification, local production, and new procurement models to manage costs and ensure business continuity. Adaptive sourcing strategies and regional alliances are becoming essential in mitigating exposure to global trade headwinds.

Methodology & Data Sources

Findings are grounded in a multi-tiered methodology, combining qualitative interviews with subject-matter experts, in-depth review of peer-reviewed publications, regulatory guidelines, and proprietary databases. Data triangulation and analytical frameworks support comprehensive evaluation and enhance reliability for strategic planning.

Why This Report Matters

  • Delivers a holistic market view to support strategy formulation, investment decisions, and portfolio expansion.
  • Enables benchmarking of technology adoption, emerging trends, and regional opportunities for scalable growth.
  • Provides actionable recommendations for mitigating operational risks and adjusting to evolving trade and regulatory dynamics.

Conclusion

The central nervous system biomarkers market is advancing through technological convergence, regional adaptation, and collaborative innovation. Decision-makers equipped with these insights can strategically navigate opportunities and safeguard market leadership as demand for diagnostic precision rises.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Central Nervous System Biomarkers Market, by Type
8.1. Introduction
8.2. Genomic Biomarkers
8.3. Metabolomic Biomarkers
8.4. Proteomic Biomarkers
9. Central Nervous System Biomarkers Market, by Disease Indication
9.1. Introduction
9.2. Neurodegenerative Diseases
9.3. Neurodevelopmental Disorders
9.4. Psychotic Disorders
10. Central Nervous System Biomarkers Market, by Technology
10.1. Introduction
10.2. Immunoassay
10.2.1. ELISA
10.2.2. Western Blot
10.3. Mass Spectrometry
10.3.1. Gas Chromatography Coupled
10.3.2. Liquid Chromatography Coupled
10.4. Next-Generation Sequencing
10.4.1. Targeted Sequencing
10.4.2. Whole Genome Sequencing
11. Central Nervous System Biomarkers Market, by Application
11.1. Introduction
11.2. Diagnosis & Therapeutics
11.3. Drug Discovery & Development
11.4. Personalized Medicine
11.5. Prognosis
11.6. Research & Development
12. Central Nervous System Biomarkers Market, by End-User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Healthcare Providers
12.4. Pharmaceutical Companies
13. Americas Central Nervous System Biomarkers Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Central Nervous System Biomarkers Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Central Nervous System Biomarkers Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Abbvie Inc.
16.3.3. Acumen Pharmaceuticals Inc.
16.3.4. ADx NeuroSciences NV
16.3.5. Agilent Technologies, Inc.
16.3.6. Altoida
16.3.7. Becton, Dickinson and Company
16.3.8. Bio-Rad Laboratories, Inc.
16.3.9. BioMérieux SA
16.3.10. Bruker Corporation
16.3.11. C2N Diagnostics, LLC
16.3.12. Cerevance, LLC
16.3.13. Charles River Laboratories International, Inc.
16.3.14. Eli Lilly and Co.
16.3.15. F. Hoffmann-La Roche AG
16.3.16. Invicro LLC
16.3.17. Johnson & Johnson Services Inc.
16.3.18. Laboratory Corporation of America Holdings
16.3.19. Mediford Corporation
16.3.20. Merck & Co., Inc.
16.3.21. Myriad Genetics, Inc.
16.3.22. Neurotrack Technologies, Inc.
16.3.23. Novartis AG
16.3.24. Qiagen N.V.
16.3.25. Quanterix Corporation
16.3.26. Sanofi SA
16.3.27. Shimadzu Corporation
16.3.28. Siemens Healthineers
16.3.29. SynapCell
16.3.30. Thermo Fisher Scientific Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET MULTI-CURRENCY
FIGURE 2. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET MULTI-LANGUAGE
FIGURE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 59. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 60. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 61. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 106. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 108. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 109. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 114. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 116. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 132. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 133. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 134. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 138. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 140. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 141. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 186. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 188. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 189. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 190. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 194. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 196. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 197. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 218. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 220. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 221. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 228. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 229. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 242. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 244. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 245. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 250. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 252. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 253. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 254. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 273. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 274. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 275. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 277. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 278. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 279. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 282. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 283. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 285. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 286. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 287. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 290. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 291. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 293. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 294. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 295. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Central Nervous System Biomarkers market report include:
  • Abbott Laboratories
  • Abbvie Inc.
  • Acumen Pharmaceuticals Inc.
  • ADx NeuroSciences NV
  • Agilent Technologies, Inc.
  • Altoida
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMérieux SA
  • Bruker Corporation
  • C2N Diagnostics, LLC
  • Cerevance, LLC
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • Invicro LLC
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Mediford Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Neurotrack Technologies, Inc.
  • Novartis AG
  • Qiagen N.V.
  • Quanterix Corporation
  • Sanofi SA
  • Shimadzu Corporation
  • Siemens Healthineers
  • SynapCell
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.5 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Central Nervous System Biomarkers - Global Strategic Business Report - Product Image

Central Nervous System Biomarkers - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Central Nervous System Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Central Nervous System Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Central Nervous System Biomarkers Market Report 2025 - Product Image

Central Nervous System Biomarkers Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
2025 Global Forecast for Central Nervous System Biomarkers Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Central Nervous System Biomarkers Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the CNS Marker Market

Biomarkers are biological molecules that can be used to measure and monitor the progression of a disease or condition. The Central Nervous System (CNS) Marker market is a subset of the biomarker market that focuses on the development of biomarkers for neurological diseases and disorders. CNS Markers are used to diagnose, monitor, and treat neurological diseases and disorders, such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. They are also used to measure the effectiveness of treatments and to predict the risk of developing neurological diseases. CNS Markers are typically proteins, peptides, or metabolites that are found in the cerebrospinal fluid, blood, or other bodily fluids. They can be used to detect the presence of a neurological disorder, to monitor the progression of the disorder, and to measure the effectiveness of treatments. Some companies in the CNS Marker market include Bio-Rad Laboratories, Bio-Techne, and Abcam. Other companies include Bio-Techne, Abcam, and Bio-Rad Laboratories. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.